NCBiotech News

Durham-based Aerie Pharmaceuticals will be acquired by Alcon, the world’s largest eye-care devices company, for about $770 million following a definitive merger agreement.

NightHawk Biosciences has announced plans to build a new advanced biosafety level 2 laboratory that will add biodefense and infectious disease capabilities at its Morrisville headquarters site.

ABEC, a Pennsylvania-based global provider of specialized products and services for biomanufacturing companies, will invest $11 million by the end of 2024 and hire some 250 people at a Wilson production facility.

GreenLight Biosciences has gotten the green light for $109 million in additional funding to help finance the development of its ribonucleic acid (RNA)-based technology for agricultural and human applications.

The U.S. Regenerative Cotton Fund, an initiative of the Morrisville-based global nonprofit Soil Health Institute, received a $2 million grant this month from the Walmart Foundation to safeguard and enhance the vitality and productivity of soils.

A multidisciplinary team of researchers led by Duke University will undertake an ambitious endeavor to understand and improve the microbial communities that inhabit the structures in which we live, work and play — what scientists call the “built environment.”

Durham-based InnAVasc Medical, a medical device company that received early funding from NCBiotech, has been acquired by W. L. Gore & Associates.

Catalent is buying Greenville-based contract development and manufacturing organization (CDMO) Metrics Contract Services.

District C, a Raleigh nonprofit, has created a new workforce development approach that gives high school students an opportunity to build collaboration and problem-solving skills through what the organization refers to as “purposeful coaching.”

Morrisville-based Metabolon will collaborate with Mayo Clinic to develop novel metabolomic biomarkers for detecting various diseases.

RTP-based BioAesthetics has announced an additional clinical trial of its NACgraft, a biologically derived allograft for patients needing nipple reconstruction, to investigate its use of in male and female patients.

An FDA decision to grant broader emergency use authorization to Qorvo Biotechnologies’ COVID diagnostic test is significantly expanding the product’s reach.

Durham-based CytexOrtho is developing an innovative new implant technology to restore cartilage and bone in damaged or diseased joints that don’t normally heal on their own.

Raleigh-based Marius Pharmaceuticals has received federal approval for its first drug.

Durham biotech firm EpiCypher is dropping a patent infringement lawsuit against one of its main competitors, California-based Active Motif, to pursue a “mutual” cross-licensing agreement of their respective IP.